NeuroSense Therapeutics Ltd., a foreign private issuer, has reported to the United States Securities and Exchange Commission (SEC) in its Form 6-K filing for August 2024. The company had previously been notified on June 21, 2024, of its non-compliance with Nasdaq's Listing Rule 5550(b), as its stockholders' equity was below the minimum requirement of $2,500,000. In response, NeuroSense Therapeutics requested a hearing with the Nasdaq Hearings Panel, which took place on August 1, 2024. During the hearing, the company presented a plan to regain compliance. On August 25, 2024, NeuroSense Therapeutics received a favorable decision from the Panel, granting an exception to remain listed on the Nasdaq Capital Market until October 31, 2024. This extension provides the company with additional time to meet the listing rule's conditions. The Form 6-K filing is also incorporated by reference into the company's registration statements on Form F-3 and Form S-8, as filed with the SEC.

NeuroSense Therapeutics Ltd., a foreign private issuer, has reported to the United States Securities and Exchange Commission (SEC) in its Form 6-K filing for August 2024. The company had previously been notified on June 21, 2024, of its non-compliance with Nasdaq's Listing Rule 5550(b), as its stockholders' equity was below the minimum requirement of $2,500,000. In response, NeuroSense Therapeutics requested a hearing with the Nasdaq Hearings Panel, which took place on August 1, 2024. During the hearing, the company presented a plan to regain compliance. On August 25, 2024, NeuroSense Therapeutics received a favorable decision from the Panel, granting an exception to remain listed on the Nasdaq Capital Market until October 31, 2024. This extension provides the company with additional time to meet the listing rule's conditions. The Form 6-K filing is also incorporated by reference into the company's registration statements on Form F-3 and Form S-8, as filed with the SEC.